Posts by: Vijaya Iyer

News

Promedior plans to begin Phase 3 testing of its investigational therapy PRM-151 for the treatment of idiopathic pulmonary fibrosis (IPF), now that the U.S. Food and Drug Administration has ... Read more

November 5, 2018November 8, 2018

Phase 2 Trial Now Underway to Test Galapagos’ GLPG1205 in IPF Patients

News

Galapagos has launched a Phase 2 trial testing the safety and effectiveness of their investigational new therapy called GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF), reporting that the first ... Read more

October 26, 2018November 2, 2018

IPF and Interstitial Lung Disease in Rheumatoid Arthritis Share Genetic Risk Factor

News

A mutation associated with the mucous-producing gene MUC5B, a known genetic risk factor for idiopathic pulmonary fibrosis (IPF), also is prevalent in rheumatoid arthritis patients with interstitial lung disease (ILD), ... Read more

October 8, 2018October 11, 2018

X-Rx Completes Early Studies on X-165 for Potential IPF Treatment, Supporting IND Application

News

Studies supporting an investigational new drug (IND) application for X-165, a potential candidate for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders, have been completed, X-Rx ... Read more

September 11, 2018September 11, 2018

American Lung Association Marks Pulmonary Fibrosis Awareness Month with Online Support Events, Videos

News

The American Lung Association is promoting Pulmonary Fibrosis Awareness Month through September with educational videos featuring lung transplant recipient Randy Cooke, who shares his tips and experience in dealing with ... Read more

August 29, 2018August 29, 2018

Male Gender, Smoking Identified as Risk Factors for Lung Cancer in IPF Patients, Study Finds

News

Lung cancer is more prevalent among men with idiopathic pulmonary fibrosis (IPF) than women, and affects smokers at a higher rate, according to a systematic review of published studies. Researchers also ... Read more

August 22, 2018August 27, 2018

European IPF Registry Helps Identify Risk Factors, Better Treatments for IPF Patients, Study Reports

News

The European IPF registry offers important insights into the characteristics, care management, and outcomes of idiopathic pulmonary fibrosis (IPF) patients in Europe, a study reports. Data from the registry showed ... Read more

Posts by: Vijaya Iyer

Vijaya Iyer

Promedior’s Experimental IPF Therapy PRM-151 to Enter Phase 3 Stage

Phase 2 Trial Now Underway to Test Galapagos’ GLPG1205 in IPF Patients

IPF and Interstitial Lung Disease in Rheumatoid Arthritis Share Genetic Risk Factor

X-Rx Completes Early Studies on X-165 for Potential IPF Treatment, Supporting IND Application

American Lung Association Marks Pulmonary Fibrosis Awareness Month with Online Support Events, Videos

Male Gender, Smoking Identified as Risk Factors for Lung Cancer in IPF Patients, Study Finds

European IPF Registry Helps Identify Risk Factors, Better Treatments for IPF Patients, Study Reports

Pin It on Pinterest